

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8291345

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FRIEDERIKE GIESEKE	03/30/2017
UGUR SAHIN	03/28/2017
RECEIVING PARTY DATA	
Name:	BIONTECH RNA PHARMACEUTICALS GMBH
Street Address:	AN DER GOLDGRUBE 12
City:	MAINZ
State/Country:	GERMANY
Postal Code:	55131
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	17245605
Application Number:	18516006
CORRESPONDENCE DATA	
Fax Number:	(617)812-1277
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9783990159
Email:	docketing@mcneillbaur.com, juliana.merlino@mcneillbaur.com
Correspondent Name:	MCNEILL BAUR PLLC
Address Line 1:	125 CAMBRIDGE PARK DRIVE
Address Line 2:	SUITE 301
Address Line 4:	CAMBRIDGE, MASSACHUSETTS 02140
ATTORNEY DOCKET NUMBER:	01183-0001-01US-T1
NAME OF SUBMITTER:	JULIANA MERLINO
SIGNATURE:	/Juliana Merlino/
DATE SIGNED:	11/22/2023
Total Attachments: 2	
source=01183-0001-60US_inventors to BioNTech_assignment#page1.tif	
source=01183-0001-60US_inventors to BioNTech_assignment#page2.tif	

ASSIGNMENT

WHEREAS We, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

THERAPEUTIC mRNA

for which a provisional United States patent application was filed on February 28, 2017 (Application No. 62/464,981); and,

WHEREAS, BioNTech RNA Pharmaceuticals GmbH, a corporation of Germany whose post office address is An der Goldgrube 12, Mainz, 55131 Germany (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this provisional patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this provisional application, and in and to any Letters Patent to be issued upon this provisional application or on an application claiming priority to this provisional application in any jurisdiction throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, We, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this provisional application, and to all applications in any worldwide jurisdiction that claim priority to this provisional application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. We have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above provisional application. We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that We have the full right to convey the interest assigned by this Assignment, and We have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

IN TESTIMONY WHEREOF, We have hereunto set our hands.

Name: Friederike Gieseke
Address: C/O BioNTech AG
An der Goldgrube 12, 55131 Mainz, Germany
By: [Signature]
Date: 30 Mar 2017


Witnessed by: [Signature]
Name: Thomas Engelen


Name: Ugur Sahin
Address: C/O BioNTech AG
An der Goldgrube 12, 55131 Mainz
Germany
By: [Signature]
Date: 28 March 2017

Witnessed by: [Signature]
Name: Thomas Engelen

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S name to this Assignment on the date indicated below.

Assignee: BioNTech RNA Pharmaceuticals GmbH
Address: An der Goldgrube 12
Mainz, 55131 Germany

Witnessed by: 
Name: Thomas Engel

By: 
Name: Dr. Siebke Pectin
Title: Managing Director
Date: April 2nd, 2017